Supercharged immune cells take on Hard-to-Treat head and neck cancer

NCT ID NCT07101432

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage trial tests a new therapy made from cord blood immune cells that are engineered to better target and attack head and neck cancer cells. Up to 33 patients with advanced disease that has not responded to standard treatments will receive these cells along with low-dose radiation and chemotherapy. The main goal is to find a safe dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
engineered natural killer (NK) cells (TROP2 CAR/IL-15 TGFBR2 KO NK cells)
What this could lead to
If successful, this could point toward a new treatment option for advanced head and neck cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 33 participants, focused on safety. The treatment may not work, and there are risks from chemotherapy and radiation used in the process.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Texas M. D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.